Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 4/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090600 | 0.81 | RAB9A (0.45) | MAPK1CYP2C9LMNA | |
| SCHEMBL2093588 | 0.80 | LMNA (0.43) | MAPK1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL2091533 | 0.79 | CRACR2A (0.46) | MAPK1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL2091612 | 0.74 | STIM1 (0.55) | MAPK1CYP2C9TP53MEN1KMT2A | |
| SCHEMBL27717245 | 0.72 | RAB9A (0.54) | CYP2C9LMNAMEN1KMT2A | |
| SCHEMBL27717112 | 0.72 | KDM4E (0.47) | MAPK1LMNATP53KMT2A | |
| SCHEMBL2096523 | 0.72 | NPC1 (0.50) | MAPK1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL27697216 | 0.71 | RAB9A (0.47) | LMNATP53MEN1KMT2A | |
| SCHEMBL13815658 | 0.70 | TRPV1 (0.49) | MAPK1LMNATP53MEN1KMT2A | |
| SCHEMBL27697212 | 0.70 | MAPT (0.53) | CYP2C9LMNATP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | MAPK1 1620/4885CYP3A4 1068/4885CYP2C9 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.